An active efflux system for heavy metals in cisplatin-resistant human KB carcinoma cells.

The mechanism for cisplatin resistance in cisplatin-resistant KCP-4 cells was studied. Although multidrug resistance-associated protein (MRP) was not detected in KCP-4 cells, the cells were more resistant to heavy metals than multidrug-resistant C-A120 cells that overexpressed MRP. KCP-4 cells expressed metallothionein, but it was scarcely involved in cisplatin resistance in these cells. KCP-4 cells did not express canalicular multispecific organic anion transporter (cMOAT). The glutathione (GSH) level was 4.7-fold higher in KCP-4 cells than in KB-3-1 cells. When the GSH level in KCP-4 cells was decreased by treating the cells with buthionine sulfoximine and nitrofurantoin, the accumulation of and sensitivity to cisplatin in the cells were increased. C-A120 cells were only 3.0-fold more resistant to cisplatin than KB-3-1 cells and this resistance was not affected by the increased glutathione level. The accumulation of platinum in C-A120 and KCP-4 cells was 68.5 and 20.4% of that in KB-3-1 cells, respectively, while the intracellular levels of antimony potassium tartrate in C-A120 and KCP-4 cells were 13.2 and 9.9% of that in KB-3-1 cells, respectively. The ATP-dependent efflux of antimony was enhanced in both C-A120 and KCP-4 cells. These results, taken together, suggest an efflux pump for heavy metals different from MRP and cMOAT is involved in cisplatin resistance in KCP-4 cells.

[1]  K. Kohno,et al.  A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. , 1996, Cancer research.

[2]  T. Aikou,et al.  Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells. , 1996, Biochemical and biophysical research communications.

[3]  T. Ishikawa,et al.  Coordinated Induction of MRP/GS-X Pump and γ-Glutamylcysteine Synthetase by Heavy Metals in Human Leukemia Cells* , 1996, The Journal of Biological Chemistry.

[4]  P. A. Rea,et al.  The Yeast Cadmium Factor Protein (YCF1) Is a Vacuolar Glutathione S-Conjugate Pump (*) , 1996, The Journal of Biological Chemistry.

[5]  P. Bosma,et al.  Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.

[6]  N. Saijo,et al.  Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. , 1995, Biochemical and biophysical research communications.

[7]  T. Kondo,et al.  Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. , 1995, Cancer research.

[8]  R. Perez,et al.  Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells. , 1995, Gynecologic oncology.

[9]  F. Baas,et al.  Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. de Vries,et al.  Role of the glutathione S-conjugate pump in cisplatin resistance. , 1995, Journal of the National Cancer Institute.

[11]  S. Howell,et al.  Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. , 1995, The Journal of clinical investigation.

[12]  P. Borst,et al.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Howell,et al.  Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. , 1994, Cancer Research.

[14]  M. Mutoh,et al.  Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells. , 1994, Journal of the National Cancer Institute.

[15]  G. M. Wilson,et al.  Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. , 1994, Cancer research.

[16]  D. Keppler,et al.  The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. , 1994, The Journal of biological chemistry.

[17]  D. Keppler,et al.  ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. , 1994, Cancer research.

[18]  F. Baas,et al.  The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Akiyama,et al.  Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein , 1994, Somatic cell and molecular genetics.

[20]  S. Aaronson,et al.  Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. , 1994, Cancer research.

[21]  M. Mutoh,et al.  Active Efflux System for Cisplatin in Cisplatin‐resistant Human KB Cells , 1994, Japanese journal of cancer research : Gann.

[22]  D. Hipfner,et al.  Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. , 1994, Cancer research.

[23]  T. Ishikawa,et al.  Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. , 1993, The Journal of biological chemistry.

[24]  M. Center,et al.  The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. , 1993, Cancer research.

[25]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[26]  L. Kèlland,et al.  Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. , 1992, British Journal of Cancer.

[27]  N. Mulder,et al.  Modulation of cis-diamminedichloroplatinum(II) resistance: a review. , 1992, British Journal of Cancer.

[28]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  L. Kèlland,et al.  The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. , 1991, British Journal of Cancer.

[30]  A. Eastman,et al.  Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. , 1991, The Journal of clinical investigation.

[31]  A. Eastman,et al.  Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. , 1987, Cancer research.

[32]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[33]  I. Pastan,et al.  Isolation and genetic characterization of human KB cell lines resistant to multiple drugs , 1985, Somatic cell and molecular genetics.

[34]  J. Kyhse-Andersen.  Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. , 1984, Journal of biochemical and biophysical methods.

[35]  P. Loehrer,et al.  Drugs five years later. Cisplatin. , 1984, Annals of internal medicine.

[36]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[37]  M. Ouellette,et al.  New mechanisms of drug resistance in parasitic protozoa. , 1995, Annual review of microbiology.